Metabolic Features of Activated Memory CD4+ T-Cells Derived from HIV-Infected Immunological Non-responders to Highly Active Antiretroviral Therapy

2021 ◽  
Vol 501 (1) ◽  
pp. 206-209
Author(s):  
V. V. Vlasova ◽  
E. V. Saidakova ◽  
L. B. Korolevskaya ◽  
N. G. Shmagel ◽  
V. A. Chereshnev ◽  
...  
2008 ◽  
Vol 81 (1) ◽  
pp. 9-15 ◽  
Author(s):  
Gautam K. Sahu ◽  
David Paar ◽  
Simon D.W. Frost ◽  
Melissa M. Smith ◽  
Scott Weaver ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-8 ◽  
Author(s):  
Vitus Sambo Badii ◽  
Kwame Ohene Buabeng ◽  
Thomas Agyarko Poku ◽  
Arnold Donkor Forkuo ◽  
Bright Boafo Boamah ◽  
...  

Tenofovir-based highly active antiretroviral therapy (HAART) is one of the preferred first-line therapies in the management of HIV 1 infection. Ghana has since 2014 adopted this recommendation; however there is paucity of scientific data that reflects the safety and efficacy of the tenofovir-based therapy compared to zidovudine in the Ghanaian health system. This study sought to assess the comparative immune reconstitution potential between tenofovir and zidovudine-based HAART regimens, which includes lamivudine and efavirenz in combination therapy. It also aimed to investigate the adverse drug reactions/events (ADREs) associated with pharmacotherapy with these agents in a total of 106 HAART naïve HIV patients. The study included 80 patients in the tenofovir cohort while 26 patients were on the zidovudine regimen. The occurrence of HIV comorbidities profile was assessed at diagnosis and throughout the study period. The baseline CD4 T cells count of the participants was also assessed at diagnosis and repeated at a median period of five months (range 4–6 months), after commencing treatment with either tenofovir- or zidovudine-based HAART. After five months of the HAART, the tenofovir cohort recorded higher CD4 T cell count change from baseline compared to the zidovudine cohort (p<0.0001). The patients on the tenofovir-based HAART and female sex however appeared to be associated with more multiple ADREs.


AIDS ◽  
2010 ◽  
Vol 24 (16) ◽  
pp. 2590-2593 ◽  
Author(s):  
Francesca Bai ◽  
Giusi M Bellistrì ◽  
Camilla Tincati ◽  
Alessia Savoldi ◽  
Alessandro Pandolfo ◽  
...  

2010 ◽  
Vol 84 (18) ◽  
pp. 9010-9018 ◽  
Author(s):  
Kenneth S. Knox ◽  
Carol Vinton ◽  
Chadi A. Hage ◽  
Lisa M. Kohli ◽  
Homer L. Twigg ◽  
...  

ABSTRACT The massive depletion of gastrointestinal-tract CD4 T cells is a hallmark of the acute phase of HIV infection. In contrast, the depletion of the lower-respiratory-tract mucosal CD4 T cells as measured in bronchoalveolar lavage (BAL) fluid is more moderate and similar to the depletion of CD4 T cells observed in peripheral blood (PB). To understand better the dynamics of disease pathogenesis and the potential for the reconstitution of CD4 T cells in the lung and PB following the administration of effective antiretroviral therapy, we studied cell-associated viral loads, CD4 T-cell frequencies, and phenotypic and functional profiles of antigen-specific CD4 T cells from BAL fluid and blood before and after the initiation of highly active antiretroviral therapy (HAART). The major findings to emerge were the following: (i) BAL CD4 T cells are not massively depleted or preferentially infected by HIV compared to levels for PB; (ii) BAL CD4 T cells reconstitute after the initiation of HAART, and their infection frequencies decrease; (iii) BAL CD4 T-cell reconstitution appears to occur via the local proliferation of resident BAL CD4 T cells rather than redistribution; and (iv) BAL CD4 T cells are more polyfunctional than CD4 T cells in blood, and their functional profile is relatively unchanged after the initiation of HAART. Taken together, these data suggest mechanisms for mucosal CD4 T-cell depletion and interventions that might aid in the reconstitution of mucosal CD4 T cells.


2002 ◽  
Vol 18 (13) ◽  
pp. 969-975 ◽  
Author(s):  
Richard L. Hengel ◽  
Maria C. Allende ◽  
Robin L. Dewar ◽  
Julia A. Metcalf ◽  
JoAnn M. Mican ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document